Rubius Therapeutics, Inc. (RUBY)
NASDAQ: RUBY · IEX Real-Time Price · USD
0.280
+0.002 (0.68%)
Jan 27, 2023, 4:00 PM EST - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Selling, General & Admin
|
53.03 | 50.34 | 57.18 | 39.89 | 22.04 | 2.45 |
| Research & Development
|
141.59 | 116.11 | 112.42 | 51.77 | 21.23 | 8.4 |
| Operating Expenses
|
194.62 | 166.45 | 169.6 | 91.66 | 43.26 | 10.85 |
| Operating Income
|
-194.62 | -166.45 | -169.6 | -91.66 | -43.26 | -10.85 |
| Interest Expense / Income
|
6.43 | 4.19 | 2.59 | 0.46 | 0.31 | 0.15 |
| Other Expense / Income
|
-4.5 | -2.9 | -8.73 | -2.93 | 0.27 | 0.02 |
| Pretax Income
|
-196.55 | -167.73 | -163.46 | -89.2 | -43.85 | -11.02 |
| Net Income
|
-196.55 | -167.73 | -163.46 | -89.2 | -43.85 | -11.02 |
| Preferred Dividends
|
0 | 0 | 0 | 0 | 0.66 | 0.75 |
| Net Income Common
|
-196.55 | -167.73 | -163.46 | -89.2 | -44.5 | -11.76 |
| Shares Outstanding (Basic)
|
88 | 81 | 79 | 39 | 8 | 7 |
| Shares Outstanding (Diluted)
|
88 | 81 | 79 | 39 | 8 | 7 |
| Shares Change
|
9.09% | 2.46% | 100.30% | 389.61% | 11.43% | - |
| EPS (Basic)
|
-2.23 | -2.08 | -2.08 | -2.27 | -5.55 | -1.63 |
| EPS (Diluted)
|
-2.23 | -2.08 | -2.08 | -2.27 | -5.55 | -1.63 |
| Free Cash Flow Per Share
|
-1.69 | -1.65 | -1.92 | -1.87 | -3.02 | -1.38 |
| EBITDA
|
-182.39 | -157.86 | -157.87 | -87.47 | -43.09 | -10.75 |
| Depreciation & Amortization
|
7.72 | 5.69 | 3 | 1.26 | 0.45 | 0.12 |
| EBIT
|
-190.11 | -163.55 | -160.87 | -88.73 | -43.54 | -10.87 |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).